Home › Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis
 

Keywords :   


Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

2014-12-10 14:44:18| Chemicals - Topix.net

Bayer HealthCare and the Drugs for Neglected Diseases initiative have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness . The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

Tags: sign agreement treatment develop

Category:Chemicals

Latest from this category

All news
12.11Benjamin Moore Expands Partnership with Roadie to Accelerate Paint Delivery for DIYers and Pros
11.11Clariant Launches Melamine-free Flame Retardant for Intumescent Coatings
11.11Protech Group Acquires Caldwell Chemical Coatings
11.11Asian Paints Reports 2Q 2024-25 Fiscal Results
10.11Clariant Launches Melamine-free Flame Retardant for Intumescent Coatings
Chemicals »
23.11 3
23.11
23.11GEN FACTORY CARVE7.7 2525.5
23.11110
23.11 ssp
23.11L
23.11
23.11 DVD-BOX6
More »